|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|
| Operating activities: | ||
| Net loss | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Change in fair value of SAFE liability | ||
| Net amortization of premiums (accretion of discounts) on available-for-sale securities | ||
| Stock-based compensation expense | ||
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | ||
| Interest receivable | ||
| Accounts payable | ||
| Accrued expenses | ||
| Net cash used in operating activities | ||
| Investing activities: | ||
| Purchases of available-for-sale securities | ||
| Proceeds on sale of available-for-sale securities | ||
| Net cash used in financing activities | ||
| Financing activities: | ||
| Proceeds from issuance of common stock in connection with the Business Combination | ||
| Proceeds From PIPE | ||
| Payment of the Business Combination and PIPE Transaction costs | ||
| Proceeds from issuance of convertible preferred stock | ||
| Payment of issuance costs for convertible preferred stock | ||
| Proceeds from issuance of convertible notes | ||
| Repayment of the Convertible Notes | ||
| Repayment of convertible notes | ||
| Cash paid for deferred offering costs | ||
| Proceeds from exercise of common stock options | ||
| Proceeds from issuance of SAFE agreements | ||
| Net cash (used) provided by financing activities | ||
| (Decrease) increase in cash and cash equivalents | ||
| Cash and cash equivalents at beginning of period | ||
| Cash and cash equivalents at end of period | ||
| Non-cash financing activities: | ||
| Conversion of Preferred Shares Into Common Shares | ||
| Unpaid Business Combination and PIPE transaction included in accounts payable and accrued expenses | ||
| Conversion of convertible preferred shares into common stock | ||
| Conversion of 2020 SAFE agreements into shares of convertible preferred stock | ||
| Other Receivable From Issuance Of Safe Agreements | ||
| Deferred offering costs included in accounts payable and accrued expenses |
Loading...
